A Regulatory Cascade that Controls Pneumococcal Capsule Biosynthesis
控制肺炎球菌胶囊生物合成的级联监管
基本信息
- 批准号:10444904
- 负责人:
- 金额:$ 39.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-23 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAffectAgeAnabolismAnimalsArchitectureBacteriaBacterial PneumoniaBiochemicalCancer EtiologyCardiomyopathiesCellsCessation of lifeCharacteristicsChildCommunitiesComplexCryoelectron MicroscopyDNADataDiseaseElderlyElementsEnvironmental Risk FactorEnzymesEpilepsyGenetic studyGlucoseGoalsGram-Positive BacteriaHumanImmune systemImmunityInfectionInvadedLifeLigandsLungMalignant NeoplasmsMedicalMethodsMicrobial BiofilmsModelingMolecularMorbidity - disease rateMutationNamesNoseOperonOxygenPathogenesisPhagocytosisPhenotypePneumococcal InfectionsPneumococcal vaccinePolysaccharidesPopulationProcessProductionProteinsPurinesRegulationResearchResolutionRoleSerotypingSet proteinSignal PathwaySignal TransductionStreptococcus pneumoniaeStressStructureSystemTherapeuticTimeTissuesUnited StatesVaccinesVirulenceVirulence FactorsVisualizationWorkalternative treatmentantimicrobialatomic interactionsbasebiological systemscapsulecommunity acquired pneumoniacrystallinityhuman diseasehuman pathogeninhibitorinsightmortalitymutantnegative affectnovelnovel therapeutic interventionparticlepathogenpreventpreventable deathpromoterrational designresponsesmall moleculestructural biologysuccesssugartranscription factorvaccine accessvirtual
项目摘要
Project Abstract
Streptococcus pneumoniae is one of the world's most debilitating human pathogens, and in the US is the most
common cause of community acquired bacterial pneumoniae, despite having an available vaccine. As the
vaccine can only contain some of the strains needed for immunity, we must find alternative treatments that
target all 93+ different versions (or serotypes) of this deadly pathogen. One of the largest problems in
pneumococcal research is understanding how this pathogen can quickly convert from a harmless nasal
commensal to invasive pathogen. Key to understanding this crucial transition is the regulation of one of S.
pneumoniae's most important virulence factors, the protective polysaccharide (sugar-based) capsule it uses to
avoid our immune system.
Our lab has now identified a crucial set of proteins that work together in S. pneumoniae, and based on their
high conservation likely many other pathogens, to enable invasiveness and disease. We have named the
collective proteins and small molecules that regulate this process the Capsule Regulatory Cascade, or CRC. In
this work we will elucidate how the CRC enables S. pneumonaie to invade the lung by understanding the
molecular and cellular interactions of this signaling network. Our methods to achieve this goal will include
looking at the CRC at the smallest level (atoms), through visualization of its action within whole live animals in
real time. Results from our studies will give unprecedented insight as to how this pathogen uses the CRC to
cause disease, paving the way for novel therapeutic strategies targeting all serotypes rather than just the
subset contained in the current vaccines. Finally, the CRC shares homology with proteins in humans that are
crucial regulators of human disease, such as cancer, cardiomyopathy and epilepsy. We thus predict that our
data will lend valuable insight into the mechanism by which these and other human diseases manifest.
项目摘要
肺炎链球菌是世界上最令人衰弱的人类病原体之一,在美国是最严重的
社区获得性细菌性肺炎的常见原因,尽管有可用的疫苗。作为
疫苗只能包含免疫所需的部分毒株,我们必须找到替代疗法
针对这种致命病原体的所有93+不同版本(或血清型)。最大的问题之一是
肺炎球菌的研究正在了解这种病原体如何迅速从无害的鼻腔
与侵袭性病原体共生。理解这一关键转变的关键是对S。
肺炎杆菌最重要的毒力因子,它使用的保护性多糖(糖基)胶囊
避开我们的免疫系统。
我们的实验室现在已经确定了一组关键的蛋白质,这些蛋白质在肺炎链球菌中协同工作,并基于它们的
高度保守,可能有许多其他病原体,以使侵袭性和疾病。我们已将
调控这一过程的集体蛋白质和小分子称为胶囊调节级联,简称CRC。在……里面
在这项工作中,我们将阐明CRC如何使肺炎链球菌通过了解
这个信号网络的分子和细胞相互作用。我们实现这一目标的方法包括
在最小的水平上(原子)观察CRC,通过可视化它在整个活动物体内的作用
实时的。我们的研究结果将为这种病原体如何利用CRC提供前所未有的见解
导致疾病,为新的治疗策略铺平了道路,针对所有血清型,而不仅仅是
当前疫苗中包含的子集。最后,CRC与人类中的蛋白质有同源性
人类疾病的关键调节因素,如癌症、心肌病和癫痫。因此我们预测我们的
数据将为这些和其他人类疾病的表现机制提供宝贵的洞察力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW T ULIJASZ其他文献
ANDREW T ULIJASZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW T ULIJASZ', 18)}}的其他基金
A novel family of conserved glyoxal toxicity response proteins.
一个新的保守乙二醛毒性反应蛋白家族。
- 批准号:
10365682 - 财政年份:2022
- 资助金额:
$ 39.62万 - 项目类别:
A novel family of conserved glyoxal toxicity response proteins.
一个新的保守乙二醛毒性反应蛋白家族。
- 批准号:
10555214 - 财政年份:2022
- 资助金额:
$ 39.62万 - 项目类别:
A Regulatory Cascade that Controls Pneumococcal Capsule Biosynthesis
控制肺炎球菌胶囊生物合成的级联监管
- 批准号:
10001426 - 财政年份:2019
- 资助金额:
$ 39.62万 - 项目类别:
A Regulatory Cascade that Controls Pneumococcal Capsule Biosynthesis
控制肺炎球菌胶囊生物合成的级联监管
- 批准号:
10216972 - 财政年份:2019
- 资助金额:
$ 39.62万 - 项目类别:
A Regulatory Cascade that Controls Pneumococcal Capsule Biosynthesis
控制肺炎球菌胶囊生物合成的级联监管
- 批准号:
10666412 - 财政年份:2019
- 资助金额:
$ 39.62万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Fellowship Programs